TB-500

Thymosin Beta-4 Fragment

Also known as: TB4, Thymosin Beta-4

Low Risk

Healing & Recovery

A synthetic version of Thymosin Beta-4, naturally occurring in nearly all human cells. Promotes cell migration, blood vessel growth, and reduces inflammation.

Benefits

Promotes progenitor cell differentiation

Supports angiogenesis and vascular growth

Reduces inflammation systemically

Enhances connective tissue and joint repair

Improves flexibility, reduces adhesion

Synergistic with BPC-157 ("Wolverine Stack")

Side Effects & Risks

Injection site redness/swellingmild

Rare fatigue or dizzinessmild

Potential blood pressure changesmoderate

Dosing Information

Typical Dose

2-2.5 mg twice/week (loading), then once/week

Administration

Subcutaneous or intramuscular injection

Cycle Length

4-8 weeks

Notes

Often combined with BPC-157 for synergistic effects

Legal Status

FDA Status

Not FDA-approved

Availability

Research chemical

WADA Status

Banned by WADA (athletes beware)

Evidence

Evidence LevelLow-Moderate

Well-studied in animal models. Used in veterinary medicine. Note: most trials used full Thymosin Beta-4 protein, not the TB-500 fragment. Limited direct human evidence for TB-500 specifically.